HZNP:NGS-Horizon Pharma plc

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing

USD 28.21

Change

+0.55 (+1.99)%

Market Cap

USD 3.42B

Volume

1.38M

Analyst Target

USD 25.27
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-19 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing HZNP

AIIQ 0.00 % 0.79 %

N/A

N/A
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

-0.05 (0%)

USD 0.50B
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

-1.75 (0%)

USD 0.50B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+0.45 (+0%)

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 44.37% 72% C 87% B+
Dividend Return N/A N/A N/A N/A F
Total Return 44.37% 72% C 87% B+
Trailing 12 Months  
Capital Gain 92.56% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 92.56% 93% A 96% N/A
Trailing 5 Years  
Capital Gain 76.09% 86% B+ 77% C+
Dividend Return N/A N/A N/A N/A F
Total Return 76.09% 86% B+ 74% C
Average Annual (5 Year Horizon)  
Capital Gain 21.39% 81% B- 79% B-
Dividend Return 21.39% 79% B- 78% C+
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 62.91% 19% F 13% F
Risk Adjusted Return 33.99% 76% C+ 50% F
Market Capitalization 3.42B 86% B+ 89% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -61.33 92% 95%
Price/Book Ratio 5.20 33% 21%
Price / Cash Flow Ratio 5.79 10% 15%
Price/Free Cash Flow Ratio 26.87 5% 17%
Management Effectiveness  
Return on Equity -8.04% 67% 35%
Return on Invested Capital 0.36% 77% 47%
Return on Assets -1.84% 74% 41%
Debt to Equity Ratio 206.50% 15% 10%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.